Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Aevi Genomic Medicine, Inc. (CERC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/11/2020 |
4
| COLA MICHAEL F (CEO) has filed a Form 4 on Aevi Genomic Medicine, LLC|
Txns:
| Bought 100,000 shares
@ $2.5, valued at
$250k
|
|
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 02/14/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/14/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/14/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/12/2020 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0.5% stake in Aevi Genomic Medicine, Inc. |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/12/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/12/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/12/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/12/2020 |
RW
| Form RW - Registration Withdrawal Request: |
| 02/07/2020 |
4
| ASTRAZENECA PLC (10% Owner) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Bought 12,946,900 shares
@ $0 |
|
| 02/07/2020 |
3
| ASTRAZENECA PLC (10% Owner) has filed a Form 3 on Aevi Genomic Medicine, Inc. |
| 02/07/2020 |
SC 13D
| ASTRAZENECA PLC reports a 16.7% stake in AEVI GENOMIC MEDICINE, INC. |
| 02/05/2020 |
4
| BARER SOL J (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 200,000 options to buy
@ $5.22, valued at
$1M
Disposed/sold 200,000 options to buy
@ $5.22, valued at
$1M
Disposed/sold 15,000 options to buy
@ $7.25, valued at
$108.8k
Disposed/sold 15,000 options to buy
@ $6.5, valued at
$97.5k
Disposed/sold 80,000 options to buy
@ $7.01, valued at
$560.8k
Disposed/sold 80,000 options to buy
@ $4.83, valued at
$386.4k
Disposed/sold 80,000 options to buy
@ $1.32, valued at
$105.6k
Disposed/sold 100,000 options to buy
@ $1.55, valued at
$155k
Disposed/sold 74,912 warrants
@ $2.84, valued at
$212.8k
|
|
| 02/05/2020 |
4
| McInaw Michael (Interim CFO) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 16,107 shares
@ $0
Disposed/sold 6,500 options to buy
@ $5.77, valued at
$37.5k
Disposed/sold 1,500 options to buy
@ $4.91, valued at
$7.4k
Disposed/sold 5,000 options to buy
@ $1.24, valued at
$6.2k
Disposed/sold 5,000 options to buy
@ $1.32, valued at
$6.6k
Disposed/sold 26,250 options to buy
@ $1.55, valued at
$40.7k
Disposed/sold 6,500 options to buy
@ $1.52, valued at
$9.9k
|
|
| 02/05/2020 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 59,524 shares
@ $0
Disposed/sold 50,000 options to buy
@ $1.55, valued at
$77.5k
Disposed/sold 20,000 options to buy
@ $1.32, valued at
$26.4k
Disposed/sold 20,000 options to buy
@ $4.83, valued at
$96.6k
Disposed/sold 40,000 options to buy
@ $8.09, valued at
$323.6k
Disposed/sold 10,591 options to buy
@ $2.84, valued at
$30.1k
|
|
| 02/05/2020 |
4
| Bayley Matthew D (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 40,000 options to buy
@ $1.25, valued at
$50k
Disposed/sold 50,000 options to buy
@ $1.55, valued at
$77.5k
|
|
| 02/05/2020 |
4
| GRANO JOSEPH J JR (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 75,683 shares
@ $0
Disposed/sold 27,000 shares
@ $0
Disposed/sold 56,780 shares
@ $0
Disposed/sold 15,384 shares
@ $0
Disposed/sold 15,000 options to buy
@ $6.5, valued at
$97.5k
Disposed/sold 20,000 options to buy
@ $7.01, valued at
$140.2k
Disposed/sold 20,000 options to buy
@ $1.32, valued at
$26.4k
Disposed/sold 50,000 options to buy
@ $1.55, valued at
$77.5k
Disposed/sold 20,000 options to buy
@ $4.83, valued at
$96.6k
Disposed/sold 7,061 warrants
@ $2.84, valued at
$20.1k
|
|
| 02/05/2020 |
4
| BAUER EUGENE A (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 165,715 shares
@ $0
Disposed/sold 28,571 options to buy
@ $8.19, valued at
$234k
Disposed/sold 50,000 options to buy
@ $6.7, valued at
$335k
Disposed/sold 20,000 options to buy
@ $7.01, valued at
$140.2k
Disposed/sold 20,000 options to buy
@ $4.83, valued at
$96.6k
Disposed/sold 20,000 options to buy
@ $1.32, valued at
$26.4k
Disposed/sold 50,000 options to buy
@ $1.55, valued at
$77.5k
Disposed/sold 3,530 warrants
@ $2.84, valued at
$10k
|
|
| 02/05/2020 |
4
| CLEMOW ALASTAIR J (Director) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 57,536 shares
@ $0
Disposed/sold 12,857 options to buy
@ $8.19, valued at
$105.3k
Disposed/sold 12,857 options to buy
@ $6.55, valued at
$84.2k
Disposed/sold 15,000 options to buy
@ $7.25, valued at
$108.8k
Disposed/sold 15,000 options to buy
@ $2.66, valued at
$39.9k
Disposed/sold 50,000 options to buy
@ $6.7, valued at
$335k
Disposed/sold 15,000 options to buy
@ $6.5, valued at
$97.5k
Disposed/sold 20,000 options to buy
@ $7.01, valued at
$140.2k
Disposed/sold 20,000 options to buy
@ $4.83, valued at
$96.6k
Disposed/sold 20,000 options to buy
@ $1.32, valued at
$26.4k
Disposed/sold 50,000 options to buy
@ $1.55, valued at
$77.5k
|
|
| 02/05/2020 |
4
| Children's Hospital of Philadelphia Foundation (10% Owner) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Acquired 38,856,891 shares
@ $0
Disposed of 57,280,927 shares
@ $0
Disposed/sold 2,824,217 options to buy
@ $2.84, valued at
$8M
|
|
| 02/05/2020 |
4
| COLA MICHAEL F (President and CEO) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 2,267,859 shares
@ $0
Disposed/sold 17,327 options to buy
@ $6.45, valued at
$111.8k
Disposed/sold 292,087 options to buy
@ $7.01, valued at
$2M
Disposed/sold 250,000 options to buy
@ $4.83, valued at
$1.2M
Disposed/sold 250,000 options to buy
@ $4.91, valued at
$1.2M
Disposed/sold 450,000 options to buy
@ $1.51, valued at
$679.5k
Disposed/sold 661,000 options to buy
@ $1.55, valued at
$1M
Disposed/sold 50,000 options to buy
@ $1.32, valued at
$66k
Disposed/sold 1,500,000 options to buy
@ $4.22, valued at
$6.3M
Disposed/sold 21,181 warrants
@ $2.84, valued at
$60.2k
|
|
| 02/05/2020 |
4
| NEIL GARRY ARTHUR (Chief Scientific Officer) has filed a Form 4 on Aevi Genomic Medicine, Inc.|
Txns:
| Disposed/sold 2,164,150 shares
@ $0
Disposed/sold 900,000 options to buy
@ $4.22, valued at
$3.8M
Disposed/sold 13,532 options to buy
@ $6.45, valued at
$87.3k
Disposed/sold 200,000 options to buy
@ $7.01, valued at
$1.4M
Disposed/sold 200,000 options to buy
@ $4.83, valued at
$966k
Disposed/sold 200,000 options to buy
@ $4.91, valued at
$982k
Disposed/sold 100,000 options to buy
@ $1.32, valued at
$132k
Disposed/sold 13,334 options to buy
@ $2.84, valued at
$37.9k
Disposed/sold 300,000 options to buy
@ $1.51, valued at
$453k
Disposed/sold 261,000 options to buy
@ $1.55, valued at
$404.6k
|
|
| 02/03/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/03/2020 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...|
Docs:
|
"Certificate of Formation of Second Genie Merger Sub, LLC",
"Limited Liability Company Agreement of Second Genie Merger Sub, LLC",
"Option Termination Agreement, effective February 3, 2020, by and between Aevi Genomic Medicine, Inc. and Michael F. Cola",
"Option Termination Agreement, effective February 3, 2020, by and between Aevi Genomic Medicine, Inc. and Garry A. Neil" |
|
| 01/06/2020 |
SC 13D/A
| Children's Hospital of Philadelphia Foundation reports a 49.1% stake in Aevi Genomic Medicine, Inc. |
|
|
|